New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 20, 2013
12:02 EDTRGRXRegeneRx receives notice of allowance from Canadian patent office
RegeneRx Biopharmaceuticals announced that it has received a Notice of Allowance of a Canadian patent application for using Thymosin beta 4 and various fragments and other related peptides for inhibiting or reversing skin aging. The patent will expire in 2021.
News For RGRX From The Last 14 Days
Check below for free stories on RGRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 21, 2014
12:39 EDTRGRXRegeneRx receives notice of allowance for U.S. patent for treatment of stroke
RegeneRx Biopharmaceuticals announced that it has received a Notice of Allowance for a second U.S. patent for treating central nervous system injuries and disorders using Thymosin beta 4 to regenerate damaged tissue. In this case, the patent will be for the treatment of patients suffering a stroke. Researchers at the Henry Ford Hospital in Detroit, Michigan, discovered Tβ4ís effects in animal studies performed under a Material Transfer Agreement between the Institution and RegeneRx. RegeneRx has received a license to the intellectual property. The patent will expire in 2026.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use